Acasti Pharma Stock Forecast, Price & News

0.00 (0.00 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3.21 million shs
Average Volume6.98 million shs
Market Capitalization$95.13 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Acasti Pharma logo

About Acasti Pharma

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.56 out of 5 stars

Medical Sector

1074th out of 2,220 stocks

Pharmaceutical Preparations Industry

505th out of 869 stocks

Analyst Opinion: 3.1Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

Is Acasti Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Acasti Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACST, but not buy additional shares or sell existing shares.
View analyst ratings for Acasti Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Acasti Pharma?

Wall Street analysts have given Acasti Pharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acasti Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decrease in short interest in June. As of June 15th, there was short interest totaling 3,170,000 shares, a decrease of 31.2% from the May 31st total of 4,610,000 shares. Based on an average trading volume of 13,100,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the company's shares are sold short.
View Acasti Pharma's Short Interest

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Acasti Pharma

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) announced its quarterly earnings results on Tuesday, June, 22nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter.
View Acasti Pharma's earnings history

How has Acasti Pharma's stock price been impacted by Coronavirus (COVID-19)?

Acasti Pharma's stock was trading at $0.3849 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACST stock has increased by 18.6% and is now trading at $0.4565.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ACST?

4 equities research analysts have issued 12-month target prices for Acasti Pharma's stock. Their forecasts range from $0.50 to $3.00. On average, they expect Acasti Pharma's share price to reach $1.75 in the next year. This suggests a possible upside of 283.4% from the stock's current price.
View analysts' price targets for Acasti Pharma
or view top-rated stocks among Wall Street analysts.

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:
  • Ms. Janelle D'Alvise, Pres, CEO, Corp. Sec. & Director (Age 65, Pay $428.04k)
  • Dr. Pierre Lemieux, Co-Founder, COO & Chief Scientific Officer (Age 56, Pay $276.38k)
  • Mr. Brian D. Ford CPA, CA, Chief Financial Officer (Age 62, Pay $364.82k)

Who are some of Acasti Pharma's key competitors?

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.46.

How much money does Acasti Pharma make?

Acasti Pharma has a market capitalization of $95.13 million and generates $200,000.00 in revenue each year.

How many employees does Acasti Pharma have?

Acasti Pharma employs 32 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is

Where are Acasti Pharma's headquarters?

Acasti Pharma is headquartered at 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company can be reached via phone at 450 687 2262 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.